 | Up a level |
2022
Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz 
ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael ORCID: 0000-0003-2645-6391, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis, V, Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Janjigian, Yelena Y.
(2022).
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature, 603 (7903).
S. 942 - 963.
BERLIN:
NATURE PORTFOLIO.
ISSN 1476-4687
2021
Janjigian, Yelena Y., Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan ORCID: 0000-0003-0808-6892, Yamaguchi, Kensei, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Schenker, Michael ORCID: 0000-0003-2645-6391, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V., Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M., Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Ajani, Jaffer A.
(2021).
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet, 398 (10294).
S. 27 - 41.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X